In addition, a combined therapy of the immune vaccine with PD-L1 can overcome the tumor immunosuppressive microenvironment, enhance tumor infiltrating CTLs, and achieve a synergistic anti-tumor effect. The gene discussed is CD274; the disease is neoplasm.